https://www.51cfo.team/en/news/ Daily US IPO, SEC filing and CFO intelligence with 51CFO analysis en https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit-4.html https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit-4.html Mon, 12 Oct 2026 06:22:34 GMT Nasdaq CEO Adena Friedman stated on October 9, 2026 that tokenization could unlock tens of billions of dollars in trapped capital — reinforcing the exchange’s strategic push into digital securities infrastructure. — 51CFO view: Tokenized assets demand new financial reporting: on-chain valuation models, cross-chain P&L attribution, and smart-contract-triggered revenue recognition. CFOs for firms with digital assets must co-design ASC 820/SAB 121-compliant frameworks — or risk audit failure pre-listing. https://www.51cfo.team/en/news/aspen-neuroscience-files-s-1-for-us-ipo.html https://www.51cfo.team/en/news/aspen-neuroscience-files-s-1-for-us-ipo.html Mon, 12 Oct 2026 06:22:34 GMT Aspen Neuroscience, Inc. (SEC file no. 0002124080), a clinical-stage neuroscience company, filed its S-1 registration statement with the SEC on October 9, 2026. The 23 MB filing signals active progress toward a U.S. IPO in the high-interest cell therapy space. — 51CFO view: CFOs for clinical-stage neuro companies must design auditable CMC cost allocation systems and reconcile non-GAAP metrics (e.g., 'per-patient manufacturing cost') to GAAP R&D expenses. Companies need CFOs fluent in both GMP compliance and SEC disclosure standards — not just accounting. https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-for-us-ipo.html https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-for-us-ipo.html Mon, 12 Oct 2026 06:22:34 GMT Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed its S-1 registration statement with the SEC on October 9, 2026. The filing, sized at 56 MB, marks its initial public offering process in the U.S. — 51CFO view: CFOs must demonstrate deep ASC 730/606 expertise for biotech S-1s — especially R&D capitalization policy, clinical-stage asset impairment modeling, and license fee revenue recognition timing. Absent this, SEC comment letters on financial disclosures become inevitable and delay timelines. https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-to-list-on-nasdaq-oct-1-2.html https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-to-list-on-nasdaq-oct-1-2.html Mon, 12 Oct 2026 06:22:34 GMT Evernorth Holdings, Inc. announced completion of its business combination with Armada Acquisition Corp. II, resulting in ~473 million XRP and $300M gross cash proceeds. Its shares will begin trading on Nasdaq on October 12, 2026 under ticker XRPN. — 51CFO view: CFOs must master ASC 805 retrospective application for SPAC mergers — including fair-value remeasurement of SPAC’s balance sheet, contingent consideration accounting, and pro forma financials. Companies targeting US listing via SPAC need CFOs with direct SPAC merger reporting experience, not just IPO background. https://www.51cfo.team/en/news/nasdaq-ytd-2026-ipo-proceeds-top-146b-exceeding-2021-record-activity-l.html https://www.51cfo.team/en/news/nasdaq-ytd-2026-ipo-proceeds-top-146b-exceeding-2021-record-activity-l.html Sun, 11 Oct 2026 18:22:34 GMT Nasdaq’s IPO Pulse report (Oct 8, 2026) states year-to-date IPO proceeds have reached $146B — surpassing the 2021 record — with momentum indicating continued activity into early 2027, reinforcing favorable conditions for new listings. — 51CFO view: Extended IPO window raises demand for CFOs who can concurrently build SOX 404(b)-compliant controls, implement SEC’s updated non-GAAP disclosure rules (Q3 2026), and document peer-group selection rationale for valuation sections — all within tight SEC review timelines. https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit-3.html https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit-3.html Sun, 11 Oct 2026 18:22:34 GMT Nasdaq CEO Adena Friedman stated on October 9, 2026 that tokenization has the potential to unlock tens of billions of dollars in capital currently trapped by traditional structures — signaling intensified exchange-level investment in digital asset infrastructure. — 51CFO view: CFOs of pre-IPO firms must anticipate ASC 350/820/860 implications for tokenized assets: defining control for classification, establishing valuation governance (e.g., crypto valuation committee), and drafting new MD&A disclosures — requiring FASB emerging-issues expertise on staff. https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-for-us-ipo-2.html https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-for-us-ipo-2.html Sun, 11 Oct 2026 18:22:34 GMT Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026, initiating its IPO process on Nasdaq or NYSE. At 56 MB, it is the largest biotech S-1 filing of the day. — 51CFO view: CFO must lead ASC 606 revenue policy design for clinical-stage collaborations, ASC 730 R&D expense/capitalization judgments, and ASC 718 equity award valuation modeling — all while establishing PCAOB-compliant financial systems and audit-ready documentation trails. https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-shares-to-trade-on-nasd-3.html https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-shares-to-trade-on-nasd-3.html Sun, 11 Oct 2026 18:22:34 GMT Evernorth Holdings, Inc. (Nasdaq: XRPN) announced completion of its business combination with Armada Acquisition Corp. II, resulting in ~473M XRP and ~$300M gross cash proceeds. Trading begins on Nasdaq on October 12, 2026. The merger triggers immediate SEC reporting obligations including Form 8-K, eligibility assessment for Form S-3, and preparation of first post-merger 10-Q. — 51CFO view: CFO must immediately handle ASC 805 business combination accounting, crypto asset valuation under ASC 350/820, and convertible instrument remeasurement. First-year SOX 404(a) readiness and dual-reporting period financial statement presentation are critical — requiring prior SPAC merger and public company SEC reporting experience. https://www.51cfo.team/en/news/nasdaq-146b-raised-in-2026-ipos-so-far-activity-expected-to-continue-i.html https://www.51cfo.team/en/news/nasdaq-146b-raised-in-2026-ipos-so-far-activity-expected-to-continue-i.html Sun, 11 Oct 2026 06:22:34 GMT Nasdaq’s IPO Pulse report states $146B raised YTD in U.S. IPOs — exceeding 2021’s full-year record — with sustained activity projected through early 2027. — 51CFO view: Extended IPO window demands CFO-led acceleration of SEC-readiness: GAAP-to-SEC reporting transition training within 6 months, XBRL/EDGAR operational fluency for finance staff, and dual-track capacity for quarterly 10-Q + S-1 drafting. https://www.51cfo.team/en/news/vistagen-therapeutics-appoints-new-cfo-and-discloses-executive-compens.html https://www.51cfo.team/en/news/vistagen-therapeutics-appoints-new-cfo-and-discloses-executive-compens.html Sun, 11 Oct 2026 06:22:34 GMT Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, reporting appointment of new CFO and related compensatory arrangements under Item 5.02. — 51CFO view: Item 5.02 filings require immediate SOX 302 certifications and full disclosure of employment agreements. For pre-IPO companies, this underscores that CFO candidates must have verifiable SEC signing authority history and documented experience leading ≥2 annual 10-K cycles. https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-with-sec-for-us-.html https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-with-sec-for-us-.html Sun, 11 Oct 2026 06:22:34 GMT Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed its S-1 registration statement with the U.S. SEC on October 9, 2026. The filing is 56 MB — indicating extensive clinical, manufacturing, and equity compensation disclosures. — 51CFO view: Large S-1 filings demand CFO oversight of ASC 718 stock comp modeling, pre-IPO GAAP-to-SEC reconciliation, and XBRL-tagged financial statement preparation. Team must support real-time EDGAR submissions and clinical-stage revenue recognition policy design. https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-shares-to-trade-on-nasd-2.html https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-shares-to-trade-on-nasd-2.html Sun, 11 Oct 2026 06:22:34 GMT Evernorth Holdings, Inc. (Nasdaq: XRPN) announced completion of its business combination with Armada Acquisition Corp. II, resulting in ~$300M gross cash proceeds and ~473M XRP held. Trading begins on Nasdaq on October 12, 2026. — 51CFO view: Post-merger CFO must immediately deliver SEC-compliant pro forma financials, SOX 404(a) readiness assessment, and ASC 805-compliant purchase accounting — including crypto asset valuation, contingent consideration modeling, and public company-level internal controls documentation. https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit-2.html https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit-2.html Sat, 10 Oct 2026 18:22:33 GMT Nasdaq CEO Adena Friedman stated on October 9, 2026 that tokenization has the potential to unlock tens of billions of dollars in 'trapped capital.' This reflects growing institutional focus on security token offerings (STOs) and blockchain-based settlement infrastructure — a trend that will reshape IPO disclosure expectations for digital assets. — 51CFO view: CFOs must anticipate SEC guidance on STO dividend mechanics, smart-contract revenue recognition, and on-chain audit trails — requiring ERP integration with blockchain ledgers and proactive engagement with SEC’s FinHub on emerging disclosure frameworks. https://www.51cfo.team/en/news/city-therapeutics-files-amended-s-1-registration-statement-s-1a.html https://www.51cfo.team/en/news/city-therapeutics-files-amended-s-1-registration-statement-s-1a.html Sat, 10 Oct 2026 18:22:33 GMT City Therapeutics, Inc. (SEC file no. 0002143850) filed an amended S-1 registration statement (S-1/A) with the SEC on October 9, 2026. The 8 MB filing is typically used to respond to SEC staff comments, update financial statements, or revise risk factors — indicating active engagement with the Division of Corporation Finance. — 51CFO view: S-1/A filings signal active SEC review. CFO must directly author responses to OCA comments on revenue recognition, related-party transactions, and VIE consolidation — demanding hands-on SEC comment letter experience, not just external advisor reliance. https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-with-sec.html https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-with-sec.html Sat, 10 Oct 2026 18:22:33 GMT Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026. The 56 MB filing signals extensive clinical trial data, intellectual property disclosures, and management discussion — typical of biotech IPOs targeting Nasdaq Capital Market. — 51CFO view: CFO must architect R&D expense capitalization policy aligned with FDA development stage gates, model stock-based compensation under ASC 718 for pre-revenue biotechs, and prepare MD&A that satisfies SEC Industry Guide 3 — requiring prior experience with NASDAQ-listed life science issuers. https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-shares-to-trade-on-nasd.html https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-shares-to-trade-on-nasd.html Sat, 10 Oct 2026 18:22:33 GMT Evernorth Holdings, Inc. (Nasdaq: XRPN) announced completion of its business combination with Armada Acquisition Corp. II, resulting in ~473 million XRP held and ~$300M gross cash proceeds. Trading begins on Nasdaq on October 12, 2026. The merger triggers immediate SEC reporting obligations under Exchange Act Rule 13a-13 and requires retrospective financial statement presentation per ASC 805. — 51CFO view: CFOs must lead complex post-merger accounting: crypto asset valuation under ASC 350-60, pro forma disclosures for non-GAAP crypto holdings, and SOX-compliant controls over digital asset custody & reconciliation — all within 4 business days of listing. https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit.html https://www.51cfo.team/en/news/nasdaq-ceo-tokenization-could-unlock-tens-of-billions-in-trapped-capit.html Sat, 10 Oct 2026 06:22:33 GMT Nasdaq CEO Adena Friedman stated on October 9, 2026, that tokenization could unlock tens of billions of dollars in trapped capital — signaling accelerated infrastructure investment and potential SEC guidance on digital securities. — 51CFO view: Emerging tokenization rules will require CFOs to define on-chain accounting entities, reconcile off-chain assets with on-chain tokens, and build dual-track financial systems. They must also explain smart contract cash flows to auditors — demanding hybrid expertise in blockchain logic, ASC 820 valuation, and SEC disclosure strategy. https://www.51cfo.team/en/news/vistagen-therapeutics-appoints-new-cfo-discloses-compensation-terms.html https://www.51cfo.team/en/news/vistagen-therapeutics-appoints-new-cfo-discloses-compensation-terms.html Sat, 10 Oct 2026 06:22:33 GMT Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, appointing a new CFO and disclosing compensatory arrangements under Item 5.02 and Item 9.01 (financial statements). — 51CFO view: CFO appointment at a public company triggers 8-K filing, 10-K updates, SOX 404 continuity review, and audit committee charter revision. For Chinese pre-IPO firms, this highlights SEC’s intensified scrutiny of executive biographies — requiring verifiable U.S. public company reporting experience and clean PCAOB audit history. https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-for-us-ipo.html https://www.51cfo.team/en/news/bambusa-therapeutics-files-s-1-registration-statement-for-us-ipo.html Sat, 10 Oct 2026 06:22:33 GMT Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. SEC on October 9, 2026, initiating its U.S. IPO process. The 56-MB filing reflects its late-stage oncology immunotherapy pipeline. — 51CFO view: Filing S-1 demands CFOs capable of preparing SEC-compliant audited financials (Regulation S-X), articulating R&D capitalization policies in MD&A, and modeling FX/inflation impacts on global clinical trials. Biotech IPOs require CFOs with FDA-SEC disclosure alignment experience and proven track record in life sciences IPO roadshows. https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-to-list-on-nasdaq-oct-1.html https://www.51cfo.team/en/news/evernorth-completes-spac-merger-with-armada-ii-to-list-on-nasdaq-oct-1.html Sat, 10 Oct 2026 06:22:33 GMT Evernorth Holdings, Inc. (Nasdaq: XRPN) announced completion of its business combination with Armada Acquisition Corp. II. Post-merger, the company holds approximately 473 million XRP and $300 million in gross cash proceeds. Shares begin trading on Nasdaq on October 12, 2026. — 51CFO view: CFOs for SPAC-target companies must master ASC 805 business combination accounting, crypto asset valuation under ASC 820, and rapid SOX 404(a) internal control implementation. This merger underscores the need for US-listed-ready finance leaders who can handle non-cash consideration disclosure, pro forma financials, and SEC-mandated retroactive restatements. https://www.51cfo.team/en/news/nasdaq-2026-us-ipo-proceeds-top-146b-exceeding-2021-record-activity-ex.html https://www.51cfo.team/en/news/nasdaq-2026-us-ipo-proceeds-top-146b-exceeding-2021-record-activity-ex.html Fri, 09 Oct 2026 18:22:33 GMT Nasdaq’s IPO Pulse report (Oct. 8, 2026) states that U.S. IPO proceeds have reached $146 billion year-to-date — surpassing the full-year 2021 record. The index indicates sustained momentum, especially for biotech and clean energy sectors, with activity projected through early 2027. — 51CFO view: This signals stable SEC review timelines but heightened disclosure rigor. Pre-IPO CFOs must initiate SOX 404(a) controls 6–9 months pre-filing, complete ≥2 rounds of PCAOB-qualified auditor pre-audits, and ensure the ‘MD&A’ section withstands short-seller scrutiny on gross margin trends and customer concentration. https://www.51cfo.team/en/news/first-horizon-cfo-hope-dmuchowski-named-to-2026-most-powerful-women-in.html https://www.51cfo.team/en/news/first-horizon-cfo-hope-dmuchowski-named-to-2026-most-powerful-women-in.html Fri, 09 Oct 2026 18:22:33 GMT Hope Dmuchowski, CFO of First Horizon Corporation (NYSE: FHN), was named to American Banker’s 2026 Most Powerful Women in Banking list — her third consecutive year on the roster. Her profile highlights leadership in post-IPO regulatory compliance, capital planning, and Federal Reserve stress test execution. — 51CFO view: This recognition reflects the multifaceted CFO profile required for U.S.-listed financial institutions: mastery of GAAP/IFRS, Fed capital frameworks (e.g., CCAR), SEC Rule 17a-4 electronic recordkeeping, and drafting of 'Risk Factors' sections in IPO prospectuses. Chinese firms targeting U.S. listings need CFOs with equivalent regulatory engagement fluency. https://www.51cfo.team/en/news/allarity-acquisition-corp-files-amended-s-1-for-spac-merger-readiness.html https://www.51cfo.team/en/news/allarity-acquisition-corp-files-amended-s-1-for-spac-merger-readiness.html Fri, 09 Oct 2026 18:22:33 GMT Allarity Acquisition Corp. (SEC file no. 0002141983), a Cayman-domiciled SPAC targeting TMT or healthcare companies in Asia or globally, filed an amended Form S-1/A on October 9, 2026. Such amendments typically reflect updated roadshow data, underwriting terms, or refined target sector criteria ahead of de-SPAC negotiations. — 51CFO view: S-1/A filings often signal de-SPAC progress or SEC comment responses. The CFO must manage push-down accounting, target financial due diligence integration, and SEC scrutiny of 'blank-check' structures. Critical competencies include PCAOB audit workpaper access and VIE-related accounting treatment expertise. https://www.51cfo.team/en/news/simwon-america-corp-files-s-1-registration-statement-with-sec.html https://www.51cfo.team/en/news/simwon-america-corp-files-s-1-registration-statement-with-sec.html Fri, 09 Oct 2026 18:22:33 GMT Simwon America Corp. (SEC file no. 0001698506) filed its Form S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026, initiating its IPO process. The 21-MB filing includes audited GAAP financials, risk factors, MD&A, and executive compensation disclosures — consistent with a U.S.-targeted biotech or medtech offering. — 51CFO view: An S-1 filing triggers immediate SEC review. The CFO must lead GAAP-compliant 3-year audited financials, SOX 404(a) internal control documentation, intercompany transaction disclosures, and cross-border tax/accounting treatments. This filing size signals readiness of a SEC-experienced finance team—not just local bookkeeping. https://www.51cfo.team/en/news/nasdaq-signals-strong-ipo-activity-through-early-2027.html https://www.51cfo.team/en/news/nasdaq-signals-strong-ipo-activity-through-early-2027.html Fri, 09 Oct 2026 06:22:32 GMT Nasdaq’s IPO Pulse reports that despite Q3 disruptions, $146B raised YTD already exceeds 2021’s full-year record. Market momentum remains strong, supporting continued IPO activity into early 2027—reinforcing the strategic value of the current window. — 51CFO view: IPO window timing directly dictates CFO resource planning: building SOX 404-compliant controls, training IR teams for SEC comment responses, and locking in U.S. financial reporting calendars (e.g., quarterly EDGAR deadlines). Missing the window triggers re-audits, legal overruns, and valuation discounts—demanding rigorous cross-time-zone project execution from the CFO. https://www.51cfo.team/en/news/lifeward-lfwd-cfo-appointment-cancelled-ahead-of-start-date.html https://www.51cfo.team/en/news/lifeward-lfwd-cfo-appointment-cancelled-ahead-of-start-date.html Fri, 09 Oct 2026 06:22:32 GMT According to Stock Titan, the CFO candidate scheduled to join Lifeward (LFWD) on November 1, 2026, will not assume the role. No reason was disclosed. Such last-minute executive appointment failures can disrupt IPO timelines or erode investor confidence for listed companies. — 51CFO view: A CFO withdrawal pre-start is a red flag for SEC reviewers. The S-1 review scrutinizes management stability—especially gaps that risk SOX 404 compliance, audit delays, or inconsistent disclosures. Pre-IPO companies must deploy an interim CFO with proven SEC filing experience—not just local finance leadership—to avoid comment letters or review suspension. https://www.51cfo.team/en/news/nexalin-technology-files-s-1a-amendment-for-ipo.html https://www.51cfo.team/en/news/nexalin-technology-files-s-1a-amendment-for-ipo.html Fri, 09 Oct 2026 06:22:32 GMT Nexalin Technology, Inc. filed an amended Form S-1/A with the SEC on October 8, 2026, updating its IPO registration. The company develops non-invasive neuromodulation devices. This amendment likely addresses SEC comments, updated financials, or underwriting terms—indicating active progress through the review process. — 51CFO view: S-1/A amendments often trigger SEC comment letters requiring CFO-led, cross-functional responses within tight deadlines. For medtech firms, this includes justifying FDA regulatory impact on revenue recognition, R&D capitalization policy under ASC 730, and intercompany cost allocations—all demanding both industry fluency and SEC response experience. https://www.51cfo.team/en/news/retension-pharmaceuticals-files-s-1-for-us-ipo.html https://www.51cfo.team/en/news/retension-pharmaceuticals-files-s-1-for-us-ipo.html Fri, 09 Oct 2026 06:22:32 GMT Retension Pharmaceuticals, Inc. filed its Form S-1 registration statement with the SEC on October 8, 2026, initiating its IPO process on NASDAQ or NYSE. The clinical-stage biopharma focuses on neurodegenerative diseases. The filing does not disclose target proceeds or ticker symbol, but marks the formal start of its U.S. listing journey. — 51CFO view: S-1 filing demands CFO-level mastery of SEC financial reporting: audited GAAP statements (3 years), SOX 404 internal controls documentation, ASC 718 stock compensation accounting, and MD&A risk quantification. For non-U.S.-trained finance leaders, this is a hard capability threshold—not just process knowledge, but judgment calibrated to SEC expectations. https://www.51cfo.team/en/news/iambic-therapeutics-files-large-s-1a-amendment-48-mb.html https://www.51cfo.team/en/news/iambic-therapeutics-files-large-s-1a-amendment-48-mb.html Thu, 08 Oct 2026 18:22:32 GMT Iambic Therapeutics, Inc. (CIK 0001997038) filed an S-1/A amendment totaling 48 MB on October 8, 2026 — the largest IPO filing of the day — indicating intensive updates to clinical data, executive bios, and risk factor disclosures. — 51CFO view: Large biotech S-1/A filings reflect heightened SEC scrutiny. CFOs must co-lead: non-GAAP R&D expense modeling tied to clinical milestones, ASC 730 R&D capitalization policy justification, medical affairs validation of risk language, and vetting executive bios for undisclosed sanctions or misconduct. https://www.51cfo.team/en/news/mes-life-safety-appoints-eric-crawford-as-cfo.html https://www.51cfo.team/en/news/mes-life-safety-appoints-eric-crawford-as-cfo.html Thu, 08 Oct 2026 18:22:32 GMT MES Life Safety, a North American leader in emergency-response and life safety solutions, appointed Eric Crawford as CFO on October 8, 2026. His profile highlights over 15 years of M&A and capital markets experience and prior service on MES’s board. — 51CFO view: A CFO with M&A experience signals potential strategic transactions. For Chinese IPO candidates, this underscores need for: cross-border integration finance skills, SEC-compliant segment reporting design, and expertise managing intercompany funding & TP documentation across VIE structures.